文献速递造血干细胞移植与细胞治疗血栓与止血

移植物抗宿主病以转化生长因子β依赖方式靶向可形成类器官的胆管干细胞

GVHD targets organoid-forming bile duct stem cells in a TGF-β-dependent manner.
PubMed 文献 · Blood · 2024-01-01

本研究探索异基因造血细胞移植后肝脏移植物抗宿主病中胆管干细胞(BDSC)的命运。异基因移植后早期胆管类器官形成效率显著增加,随后显著下降并伴胆管上皮细胞减少和血浆胆红素升高;肝浸润单核细胞以转化生长因子β依赖方式抑制类器官生长,而转化生长因子β信号抑制剂SB-431542(第14–28天给药)保护BDSC并减轻胆道功能障碍。

要点

  • 异基因移植后早期胆管类器官形成效率显著增加,随后显著下降并伴胆管上皮细胞减少和血浆胆红素升高。
  • 异基因受体肝浸润单核细胞以转化生长因子β依赖方式显著抑制肝类器官生长。
  • 第14–28天给予转化生长因子β信号抑制剂SB-431542可保护BDSC并减轻胆道功能障碍。

核心结论

  • 移植物抗宿主病靶向可形成类器官的胆管干细胞并损害胆管上皮细胞的复原能力,BDSC是肝脏移植物抗宿主病有前景的治疗靶点。

研究设计与样本

  • 研究探索异基因造血细胞移植后肝脏移植物抗宿主病中可体外生成肝类器官的胆管干细胞的命运。

主要发现

  • 异基因造血细胞移植后早期胆管上皮细胞显著扩增,胆管类器官形成效率也显著增加。
  • 随后胆管类器官形成效率显著下降,伴胆管上皮细胞减少和血浆胆红素浓度升高。
  • 异基因受体肝浸润单核细胞存在时肝类器官生长显著降低,而同基因受体来源者无此作用,且呈转化生长因子β依赖方式。

临床怎么用

  • 第14–28天给予转化生长因子β信号抑制剂SB-431542可保护可形成类器官的胆管干细胞免受移植物抗宿主病影响并减轻异基因造血细胞移植后胆道功能障碍。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) is a major life-threatening complication that occurs after allogeneic hematopoietic cell transplantation (HCT). Although adult tissue stem cells have been identified as targets of GVHD in the skin and gut, their role in hepatic GVHD is yet to be clarified. In the current study, we explored the fate of bile duct stem cells (BDSCs), capable of generating liver organoids in vitro, during hepatic GVHD after allogeneic HCT. We observed a significant expansion of biliary epithelial cells (BECs) on injury early after allogeneic HCT. Organoid-forming efficiency from the bile duct was also significantly increased early after allogeneic HCT. Subsequently, the organoid-forming efficiency from bile ducts was markedly decreased in association with the reduction of BECs and the elevation of plasma concentrations of bilirubin, suggesting that GVHD targets BDSCs and impairs the resilience of BECs. The growth of liver organoids in the presence of liver-infiltrating mononuclear cells from allogeneic recipients, but not from syngeneic recipients, was significantly reduced in a transforming growth factor-β (TGF-β)-dependent manner. Administration of SB-431542, an inhibitor of TGF-β signaling, from day 14 to day 28, protected organoid-forming BDSCs against GVHD and mitigated biliary dysfunction after allogeneic HCT, suggesting that BDSCs are a promising therapeutic target for hepatic GVHD.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hasegawa Y, Hashimoto D, Zhang Z, et al. GVHD targets organoid-forming bile duct stem cells in a TGF-β-dependent manner. Blood. 2024. PMID: 38905638. doi:10.1182/blood.2023023060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。